Cargando…
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
Patients with hematologic malignancies and recipients of hematopoietic cell transplantation (HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have a higher risk of morbidity and mortality after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249429/ https://www.ncbi.nlm.nih.gov/pubmed/35776899 http://dx.doi.org/10.1182/blood.2022016089 |